[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1979

MHPG Excretion-Reply

Author Affiliations

Clinical Neuropharmacology Branch, National Institute of Mental Health National Institutes of Health Clinical Center, Bldg 10, Rm 3D48 Bethesda, MD 20014; Fair Oaks Hospital Summit, NJ 07901; Department of Psychiatry Yale University School of Medicine New Haven, CT 06510; Connecticut Mental Health Center 34 Park St New Haven, CT 06516

Arch Gen Psychiatry. 1979;36(9):1030-1031. doi:10.1001/archpsyc.1979.01780090116014

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In Reply.—  Several comments in response to Drs Rifkin and Quitkin's letter are in order. Their statement that "only one of the four (patients) whose conditions did not improve received drugs" is not an accurate representation of the clinical data we presented. We stated that the medication of one of the four patients whose condition demonstrated no change at follow-up was stopped as part of our study. In total, the conditions of none of the ten patients included in our study were treated with tricyclic antidepressants during the patients' baseline hospitalization; the remaining patient's condition was treated with lithium. As described in our report, the medication of four patients was stopped during the course of the protocol. We did not assign patients to "responder" and "nonresponder" groups, since we were not evaluating outcome of a specific treatment regimen.The MHPG excretion data for the baseline and follow-up periods in our study

First Page Preview View Large
First page PDF preview
First page PDF preview
×